Collegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from HC Wainwright

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $50.00 price objective on the specialty pharmaceutical company's stock. HC Wainwright's price target suggests a potential upside of 51.93% from the company's current price.

COLL has been the topic of several other research reports. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target on the stock in a research report on Friday. Finally, Piper Sandler reiterated a "neutral" rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $43.80.

Collegium Pharmaceutical Trading Down 1.3 %

Shares of COLL stock traded down $0.43 on Friday, hitting $32.91. 686,743 shares of the company's stock traded hands, compared to its average volume of 622,707. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of 14.19 and a beta of 0.82. The company's fifty day simple moving average is $30.57 and its 200 day simple moving average is $34.04. Collegium Pharmaceutical has a one year low of $28.39 and a one year high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds have recently made changes to their positions in COLL. TD Private Client Wealth LLC raised its stake in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after buying an additional 483 shares in the last quarter. Foundry Partners LLC raised its position in shares of Collegium Pharmaceutical by 3.3% in the 3rd quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company's stock worth $610,000 after acquiring an additional 509 shares in the last quarter. CWM LLC lifted its stake in shares of Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock valued at $58,000 after purchasing an additional 736 shares during the period. GAMMA Investing LLC boosted its position in shares of Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 792 shares in the last quarter. Finally, Harbor Capital Advisors Inc. grew its stake in Collegium Pharmaceutical by 4.4% in the third quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company's stock worth $908,000 after purchasing an additional 983 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.